行情

AGIO

AGIO

Agios制药
NASDAQ

实时行情|Nasdaq Last Sale

37.17
+2.72
+7.90%
交易中 12:18 04/02 EDT
开盘
34.08
昨收
34.45
最高
37.64
最低
34.08
成交量
22.58万
成交额
--
52周最高
68.85
52周最低
27.77
市值
25.47亿
市盈率(TTM)
-5.4118
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGIO价格均价为64.27,最高价位80.00,最低价为42.00。

EPS

AGIO 新闻

更多
  • 特朗普料俄罗斯和沙特大规模减产 原油价格飙升
  • 新浪财经 · 1小时前
  • 瑞幸在割美国韭菜吗?前十大持仓基金究竟是谁?
  • 新浪财经 · 1小时前
  • 石油股大涨,因特朗普预期俄罗斯和沙特将减产
  • 新浪财经 · 1小时前
  • 石油三国杀要结束了?还言之尚早
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
+2.40%
制药与医学研究
+1.98%

热门股票

代码
价格
涨跌幅

AGIO 简况

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
展开

微牛提供Agios Pharmaceuticals Inc(NASDAQ-AGIO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGIO股票新闻,以帮助您做出投资决策。